Abstract:A60 The objective of this study was to investigate the influence of genetic variations in genes encoding doxorubicin metabolizing enzymes carbonyl reductases 1 and 3 ( CBR1 and CBR3 ) and ATP-binding cassette transporters ( ABCB1 and ABCC5 ) on the pharmacokinetics of doxorubicin in Asian breast cancer patients receiving adjuvant chemotherapy (N=48). Patients received doxorubicin (range: 56-61 mg/m 2 ) as a 20 minutes intravenous infusion and blood samples were collected at 0, 0.5, 1, 4, 8 and 24hrs. Non-linear mixed effect modeling was applied for the analysis of concentration-time profile of doxorubicin (NONMEM version 6). Doxorubicin pharmacokinetics was best described by a two-compartmental model, which included inter-individual variability (IIV) in terms of the fixed effect parameters [total plasma clearance (CL), the inter-compartmental clearance (Q) and the volume of distribution in central and peripheral compartments (V1 and V2)]. IIV was modeled based on an exponential relationship with fixed effect parameters and residual error model was described by the combination of additive and proportional equations. Model estimate for doxorubicin clearance (CL) was 44.7 L/h and inter-compartmental clearance (Q) was 46.8 L/h. The apparent volume of distribution in central compartment (V1) and peripheral compartment (V2) was 18.2 L and 537 L, respectively. Among the genetic and non-genetic covariates investigated, patient weight and CBR1 . 219G>C genotype showed significant associations with pharmacokinetics of doxorubicin. CBR3 which has minimal relative tissue expression compared to CBR1 did not show any influence on pharmacokinetics of doxorubicin. Weight alone explained 5.2% of inter-individual variability on doxorubicin clearance. The patients harbouring CBR1 . 219G>C observed 9% less clearance than the wild type (CL Lhr - 1: GG vs GC+CC: 48.2 ± 10.4 vs 41.8 ± 7.2; P = 0.03) and the exposure level was significantly higher in patients homozygous for the CBR1 . 219C allele (AUC μg hr L -1 : GG vs GC+CC: 1987 ± 376 vs 2275 ± 348.5; P = 0.045). The proposed population pharmacokinetic model incorporating patient weight and CBR1 genotype status explained 22% of total variability in the clearance of doxorubicin in Asian breast cancer patients. No significant association of genetic and non genetic covariates on the pharmacokinetic parameters of doxorubicinol was observed.

Research progress on pharmacogenomics of daunorubicin individual differences

Research progress in toxic effects of antitumor drugs based on drug transporter

[Personalized Dosing from Perspective of Pharmacogenomics of Drug Metabolizing Enzymes and Transporters].

Pharmacogenomics on anti-cancer drugs: research advances

Role of Aldo-Keto Reductases and Other Doxorubicin Pharmacokinetic Genes in Doxorubicin Resistance, DNA Binding, and Subcellular Localization

Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs

A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor

OR98 UPDATED OVERALL SURVIVAL (OS) OUTCOMES FROM THE PHASE 3 PHOEBE TRIAL OF PYROTINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER

Subcellular Daunorubicin Distribution and Its Relation to Multidrug Resistance Phenotype in Drug-Resistant Cell Line Smmc-7721/R

Progress of Pharmacogenomics and Individual Drug Design

Study advance in tumor pharmacogenomics

[Relationship Between Pharmacokinetics and Efficacy and Toxicity of Daunorubicin in Children with Acute Leukemia].

Advances of pharmacogenomics in colorectal cancer

Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine

Pharmacogenetic Profiling Across the Doxorubicin Pathway in Asian Breast Cancer Patients

Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia

New Era of Individualized Pharmacotherapy

Influence of Gene Polymorphisms on Efficacy of Gemcitabine: Research Advances

Naturally Occurring Variants of Human Aldo-Keto Reductases with Reduced In Vitro Metabolism of Daunorubicin and Doxorubicin

[Research Advances in Pharmacogenomics of Mercaptopurine].

Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells